FY2023 EPS Estimates for Indivior PLC Increased by Analyst (OTCMKTS:INVVY)

Indivior PLC (OTCMKTS:INVVYGet Rating) – Stock analysts at Jefferies Financial Group boosted their FY2023 EPS estimates for shares of Indivior in a report released on Tuesday, August 2nd. Jefferies Financial Group analyst J. Vane-Tempest now anticipates that the company will post earnings of $1.55 per share for the year, up from their previous estimate of $1.50. The consensus estimate for Indivior’s current full-year earnings is $1.26 per share. Jefferies Financial Group also issued estimates for Indivior’s FY2024 earnings at $1.70 EPS, FY2025 earnings at $1.70 EPS and FY2026 earnings at $1.90 EPS.

Indivior Price Performance

OTCMKTS:INVVY opened at $19.64 on Thursday. The firm has a market cap of $2.73 billion, a PE ratio of 18.70 and a beta of 0.16. Indivior has a 12 month low of $10.78 and a 12 month high of $22.58. The company has a quick ratio of 1.61, a current ratio of 1.73 and a debt-to-equity ratio of 1.03. The company’s 50-day moving average price is $18.97 and its two-hundred day moving average price is $18.53.

About Indivior

(Get Rating)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia.

Further Reading

Earnings History and Estimates for Indivior (OTCMKTS:INVVY)

Want More Great Investing Ideas?

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.